AC Immune’s Promising Trial Results for Parkinson’s Therapy
AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...
AC Immune stock jumps 20% on data for Parkinson's disease drug
AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...
Nanowerk9h
Nanodiamonds bring new hope for Parkinson's research with advanced neuronal sensing
Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...
manilatimes14h
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...
News Medical15h
Study identifies a potential treatment for Sandhoff and Tay-Sachs diseases
In a groundbreaking study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases—two rare, often fatal lysosomal storage disorders that cause ...
Benzinga.com16h
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...
The Lancet19h
Amyloid-lowering treatment in Alzheimer's disease
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...